2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. SGLT

SGLT

Sodium-dependent glucose cotransporters

SGLT

Related Products

PDF 0.51 MB

SGLTs (Sodium-dependent glucose cotransporters) are a family of glucose transporters and contribute to glucose reabsorption. The two most well-known members of SGLT family are SGLT1 and SGLT2, which are members of the SLC5A gene family. The two transporters are of primary importance for glucose homeostasis by absorbing glucose from the diet in the small intestine (via SGLT1) and by reabsorbing the filtered glucose in the tubular system of the kidney (primarily SGLT2; to smaller extent via SGLT1); the latter process returns glucose into the blood stream and prevents urinary glucose loss. SGLT1 and SGLT2 have been proposed as a novel therapeutic strategy for diabetes and cardiomyopathy.

SGLT Isoform Specific Products:

SGLT Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13413
    Tofogliflozin hydrate
    		Inhibitor 98.38%
    Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2. Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells.
    Tofogliflozin hydrate
  • HY-14894A
    Ipragliflozin L-Proline
    		Inhibitor 99.88%
    Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
    Ipragliflozin L-Proline
  • HY-15461A
    Ertugliflozin L-pyroglutamic acid
    		Inhibitor 99.84%
    Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
    Ertugliflozin L-pyroglutamic acid
  • HY-10449
    Luseogliflozin
    		Inhibitor 99.33%
    Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes.
    Luseogliflozin
  • HY-15409S
    Empagliflozin-d4
    		Inhibitor 98.40%
    Empagliflozin-d4 is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
    Empagliflozin-d<sub>4</sub>
  • HY-109018
    Velagliflozin
    		Inhibitor 99.92%
    Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
    Velagliflozin
  • HY-128723
    Dapagliflozin impurity
    		99.63%
    Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor.
    Dapagliflozin impurity
  • HY-10450S
    Dapagliflozin-d5
    		Inhibitor 99.04%
    Dapagliflozin-d5 is a deuterium labeled Dapagliflozin (HY-10450). Dapagliflozin is a competitive SGLT2 inhibitor.
    Dapagliflozin-d<sub>5</sub>
  • HY-14945
    Remogliflozin etabonate
    		Inhibitor 99.64%
    Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.
    Remogliflozin etabonate
  • HY-N0143A
    Phlorizin dihydrate
    		Inhibitor 99.51%
    Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities.
    Phlorizin dihydrate
  • HY-174400
    SGLT2-IN-2
    		Inhibitor 99.57%
    SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice.
    SGLT2-IN-2
  • HY-116223
    Tianagliflozin
    		Inhibitor 99.96%
    Tianagliflozin is a sodium/glucose cotransporter 2 (SGLT-2) inhibitor with potential for investigation in type 2 diabetes.
    Tianagliflozin
  • HY-10451S
    Canagliflozin-d4
    		Inhibitor 99.9%
    Canagliflozin-d4 (JNJ 28431754-d4) is a deuterium labeled Canagliflozin. Canagliflozin is a selective SGLT2 inhibitor.
    Canagliflozin-d<sub>4</sub>
  • HY-14902
    Tofogliflozin
    		Inhibitor 98.38%
    Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.
    Tofogliflozin
  • HY-109092
    Licogliflozin
    		Inhibitor 98.03%
    Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
    Licogliflozin
  • HY-109144
    Enavogliflozin
    		Inhibitor 98.43%
    Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
    Enavogliflozin
  • HY-10450R
    Dapagliflozin (Standard)
    		Inhibitor
    Dapagliflozin (Standard) is the analytical standard of Dapagliflozin. This product is intended for research and analytical applications. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
    Dapagliflozin (Standard)
  • HY-13414
    Remogliflozin
    		Inhibitor 99.5%
    Remogliflozin is a potent and selective inhibitor of SGLT2 (sodium-glucose cotransporter 2) with Kis of 12.4 and 26 nM for human and rat SGLT2, respectively. Remogliflozin is the active form of Remogliflozin etabonate(HY-14945).
    Remogliflozin
  • HY-101782
    HSK0935
    		Inhibitor
    HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.
    HSK0935
  • HY-N0142R
    Phloretin (Standard)
    		Inhibitor
    Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM, respectively.Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation.
    Phloretin (Standard)
SGLT Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.